|
|
|
| Factors affecting hyperglycemia among HIV/AIDS patients receiving antiretroviral therapy |
| CHEN Suting1, HONG Hang2, XU Guozhang2
|
1. School of Medicine, Ningbo University, Ningbo, Zhejiang 315211, China;
2. Ningbo Center for Disease Control and Prevention, Ningbo, Zhejiang 315010, China |
|
|
|
|
Abstract Objective To investigate the factors of hyperglycemia among HIV/AIDS patients receiving antiretroviral therapy (ART) in Ningbo City. Methods The demographic characteristics, ART and fasting blood glucose were collected from HIV/AIDS patients receiving ART in Ningbo City from 2005 to 2021 through the Ningbo Municipal ART Database. The fasting blood glucose levels were analyzed among HIV/AIDS patients receiving ART, and the factors affecting hyperglycemia were identified using a multivariable logistic regression model. Results A total of 2 607 HIV/AIDS patients were enrolled, including 2 162 men (82.93%), and the participants had a mean age of (45.16±13.93) years, and had mean ART duration of 5.00 years (interquartile range, 5.00 years). The prevalence of hyperglycemia, impaired fasting glucose and diabetes was 22.59%, 13.62% and 8.98%, respectively. Multivariable logistic regression analysis showed that gender (male, OR=1.482, 95%CI: 1.120-1.961), age (30 years-, OR=2.062, 95%CI: 1.356-3.137; 45 years-, OR=3.697, 95%CI: 2.435-5.611; 60 years and older, OR=7.295, 95%CI: 4.722-11.268), WHO clinical staging of HIV diseases (stage Ⅱ, OR=1.415, 95%CI: 1.097-1.824; stage Ⅲ, OR=1.571, 95%CI: 1.139-2.168; stage Ⅳ, OR=1.488, 95%CI: 1.040-2.128, duration of HIV infections (7 to <10 years, OR=1.336, 95%CI: 1.004-1.777), treatment regimen (second-line regimen, OR=0.611, 95%CI: 0.472-0.792), and blood lipids (high TG, OR=1.665, 95%CI: 1.307-2.123; high TC, OR=1.415, 95%CI: 1.006-1.991; dyslipidemia, OR=2.597, 95%CI: 1.971-3.422) significantly correlated with hyperglycemia. Conclusions The overall prevalence of hyperglycemia was 22.59% among HIV/AIDS patients with ART in Ningbo City, and the prevalence of hyperglycemia correlated with gender, age, clinical staging of HIV infections, duration of HIV infections, treatment regimens and blood lipids among HIV/AIDS patients.
|
|
Received: 23 June 2022
Revised: 27 September 2022
Published: 16 November 2022
|
|
|
|
|
|
[1] NOUBISSI E C,KATTE J C,SOBNGWI E.Diabetes and HIV[J/OL].Curr Diab Rep,2018(2018-10-08)[2022-09-27].https://doi.org/10.1007/s11892-018-1076-3.
[2] 张超,付钰淋,任强,等.陕西省HIV/AIDS 合并感染HBV病例分析[J].预防医学,2018,30(9):889-892.
ZHANG C,FU Y L,REN Q,et al.Analysis of HIV/AIDS patients co-infected with HBV in Shaanxi Province[J].Prev Med,2018,30(9):889-892.
[3] HERNANDEZ-ROMIEU A C,GARG S,ROSENBERG E S,et al.Is diabetes prevalence higher among HIV-infected individuals compared with the general population? Evidence from MMP and NHANES 2009-2010[J/OL].BMJ Open Diabetes Res Care,2017,5(1)[2022-09-27].http://dx.doi.org/10.1136/bmjdrc-2016-000304.
[4] GALLI L,SALPIETRO S,PELLICCIOTTA G,et al.Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy[J].Eur J Epidemiol,2012,27(8):657-665.
[5] TIEN P C,SCHNEIDER M F,COX C,et al.Association of HIV infection with incident diabetes mellitus:impact of using hemoglobin A1C as a criterion for diabetes[J].J Acquir Immune Defic Syndr,2012,61(3):334-340.
[6] 张红燕,杨丹丹,周奇文,等.cARV治疗对艾滋病患者糖代谢、脂质代谢及胰岛素抵抗的影响[J].公共卫生与预防医学,2018,29(3):84-87.
ZHANG H Y,YANG D D,ZHOU Q W,et al.Effects of cARV therapy on glucose metabolism,lipid metabolism and insulin resistance in AIDS patients[J].J Pub Health Prev Med,2018,29(3):84-87.
[7] 中华医学会糖尿病学分会.中国2型糖尿病防治指南(2020年版)(上)[J].中国实用内科杂志,2021,41(8):668-695.
Guideline for the prevention and treatment oftype 2 diabetas mellitus in China(2020 edition)(Part 1)[J].Chin J Pract Intern Med,2021,41(8):668-695.
[8] SHEN Y Z,WANG Z Y,LIU L,et al.Prevalence of hyperglycemia among adults with newly diagnosed HIV/AIDS in China[J/OL].BMC Infect Dis,2013,13[2022-09-27].http://dx.doi.org/10.1186/1471-2334-13-79.
[9] 中国成人血脂异常防治指南修订联合委员会.中国成人血脂异常防治指南(2016年修订版)[J].中华健康管理学杂志,2017,11(1):7-28.
Joint committee issued Chinese guideline for the management of dyslipidemia.2016 Chinese guideline for the management of dyslipidemia in adults[J].Chin J Health Manag, 2017,11(1):7-28.
[10] ZHAO Y,MCGOOGAN J M,WU Z Y.The benefits of immediate ART [J/OL].J Int Assoc Provid AIDS Care(2019-03-04)[2022-09-27].https://doi.org/10.1177/2325958219831714.
[11] World Health Organization.Diabetes China 2016 country profile[EB/OL].(2016-05-31)[2022-09-27].https://www.who.int/publications/m/item/diabetes-chn-country-profile-china-2016.
[12] 叶润华,李静,姚仕堂,等.德宏傣族景颇族自治州抗病毒治疗的HIV/AIDS糖尿病患病率及其相关因素分析[J].中华流行病学杂志,2019,40(6):654-659.
YE R H,LI J,YAO S T,et al.Prevalence and related factors on diabetes among HIV/AIDS receiving antiretroviral therapy in Dehong Dai and Jingpo Autonomous Prefecture[J].Chin J Epidemiol,2019,40(6):654-659.
[13] HAN W M,JIANSAKUL A,KIERTIBURANAKUL S,et al.Diabetes mellitus burden among people living with HIV from the Asia-Pacific region [J/OL].J Int AIDS Soc,2019,22(1)[2022-09-27].https://doi.org/10.1002/jia2.25236.
[14] 何佳晋,居豪,吴超.中国MSM人群HIV新发感染率及其影响因素的Meta分析[J].预防医学,2022,34(1):70-77.
HE J J,JU H,WU C.Incidence of new HIV infection and its influencing factors among men who have sex with men in China:a meta-analysis[J].Prev Med,2022,34(1):70-77.
[15] 刘甲野,孙丽琴,何云,等.深圳市初治HIV感染者高血糖患病率及影响因素分析[J].中国艾滋病性病,2020,26(6):590-594.
LIU J Y,SUN L Q,HE Y,et al.Prevalence and associated factors of hyperglucemia among antiretroviral-naïve HIV-infected individuals in Shenzhen city,China[J].Chin J AIDS STD,2020,26(6):590-594.
[16] CAPEAU J,BOUTELOUP V,KATLAMA C,et al.Ten-year diabetes incidence in 1 046 HIV-infected patients started on a combination antiretroviral treatment[J].AIDS,2012,26(3):303-314.
[17] CHIMBETETE C,MUGGLIN C,SHAMU T,et al.New-onset type 2 diabetes mellitus among patients receiving HIV care at Newlands Clinic,Harare,Zimbabwe:retrospective cohort analysis[J].Trop Med Int Health,2017,22(7):839-845.
[18] STEINICHE D,JESPERSEN S,ERIKSTRUP C,et al.Diabetes mellitus and impaired fasting glucose in ART-naive patients with HIV-1,HIV-2 and HIV-1/2 dual infection in Guinea-Bissau:a cross-sectional study[J].Trans R Soc Trop Med Hyg,2016,110(4):219-227.
[19] DUGUMA F,GEBISA W,MAMO A,et al.Diabetes mellitus and associated factors among adult HIV patients on highly active anti-retroviral treatment[J].HIV AIDS,2020,12:657-665.
[20] DUBE M P.Disorders of glucose metabolism in patients infected with human immunodeficiency virus[J].Clin Infect Dis,2000,31(6):1467-1475.
[21] ISA S E,OCHE A O,KANG'OMBE A R,et al.Human immunodeficiency virus and risk of type 2 diabetes in a large adult cohort in Jos,Nigeria[J].Clin Infect Dis,2016,63(6):830-835. |
|
|
|
